To test the hypothesis that CNAs common in both human and dog CRC are more likely to be the direct cause of CRC, Dr. Zhao ™s team used NimbleGen CGH microarrays to first characterize CNAs in human CRC and canine CRC samples. For this study, we selected the high density 385K and 2.1 million CGH arrays from Roche NimbleGen as our platform of choice to identify copy number abnormalities in sporadic canine and human colorectal cancer (CRC) genomes, as they provide comprehensive detection of known and novel CNAs, said Dr. Zhao. The results have revealed for the first time a strong degree of genetic homology between sporadic canine and human CRC. The study provides the molecular evidence supporting that sporadic canine cancers are excellent models for the corresponding human cancers, and that comparison between dog and human cancers of similar types would be a powerful way to identify driver alterations.

Supporting scientific progress through innovative microarray technologies is an important goal at Roche NimbleGen said Dr. Andreas Goertz, Vice President of Marketing. We collaborate with leading research scientists such as Dr. Zhao and her team to provide cutting edge methods such as sensitive and accurate CGH analysis on human and model organisms with our robust and comprehensive CGH microarray platform.

Source Roche